| Literature DB >> 29018263 |
Heng-Gang Yang1, Huan Zhao1, Jiao-Jiao Li1, Shao-Meng Chen1, Lang-Ming Mou1, Jian Zou1, Guo-Dong Chen1, Sheng-Ying Qin2, Chuan-Xi Wang3, Dan Hu1, Xin-Sheng Yao1, Hao Gao4,5.
Abstract
Phyllomeroterpenoids A-C (1-3), multi-biosynthetic pathway derived meroterpenoids from amino acid/pentose phosphate/terpenoid pathways, were isolated from the TCM endophytic fungus Phyllosticta sp. J13-2-12Y, together with six biosynthetically related compounds (4-9). All structures were determined by extensive spectroscopic analysis, chemical derivatization, and ECD experiments. A plausible biosynthetic pathway of 1-3 was proposed. In addition, the antimicrobial activities of all isolated compounds were evaluated against Staphylococcus aureus 209P (bacterium) and Candida albicans FIM709 (fungus).Entities:
Mesh:
Substances:
Year: 2017 PMID: 29018263 PMCID: PMC5635028 DOI: 10.1038/s41598-017-13407-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Chemical structures of 1−9.
Figure 2Key1H-1H COSY, HMBC, and NOESY correlations of 1.
NMR data of 1−3 (δ in ppm, J in Hz).
| No. | 1a | 2a | 3a | |||
|---|---|---|---|---|---|---|
|
|
c
|
|
c
|
|
c
| |
| 1 | 198.6, C | 200.1, C | 198.7, C | |||
| 2 | 102.7, C | 104.4, C | 104.0, C | |||
| 3 | 172.7, C | 174.3, C | 171.8, C | |||
| 4 | 78.3, CH | 4.54, d (5.5) | 79.9, CH | 4.52, d (5.5) | 78.0, CH | 4.53, d (5.5) |
| 5 | 44.0, CH2 | 2.45, dd (10.7, 5.5), Ha | 45.1, CH2 | 2.30, dd (10.7, 5.5), Ha | 43.9, CH2 | 2.45, Ha |
| 2.02, d (10.7), Hb | 2.07, d (10.7), Hb | 2.00, d (10.7), Hb | ||||
| 6 | 81.7, C | 83.3, C | 81.9, C | |||
| 7 | 70.5, CH2 | 3.79, d (7.9), Ha | 72.3, CH2 | 3.70, d (7.9), Ha | 70.5, CH2 | 3.80, d (7.9), Ha |
| 3.47, d (7.9), Hb | 3.49, d (7.9), Hb | 3.45, d (7.9), Hb | ||||
| 8 | 15.5, CH2 | 2.33, br d (17.1), Ha | 18.7, CH2 | 2.55, dd (17.1, 1.3), Ha | 15.0, CH2 | 2.29, Ha |
| 2.21, Hb | 2.21, dd (17.1, 5.9), Hb | 2.04, Hb | ||||
| 9 | 43.5, CH | 1.99 | 42.3, CH | 2.11, ddd (10.0, 5.9, 1.3) | 40.7, CH | 2.06 |
| 10 | 88.8, C | 91.7, C | 88.7, C | |||
| 11 | 23.0, CH3 | 1.29, s | 22.9, CH3 | 1.28, s | 18.4, CH3 | 1.14, s |
| 12 | 37.0, CH2 | 2.07, ddd (14.1, 9.2, 4.0), Ha | 38.6, CH2 | 1.89, ddd (13.1, 7.7, 1.0), Ha | 80.8, CH | 5.23, dd (6.8, 2.1) |
| 1.77, ddd (14.1, 11.7, 6.2), Hb | 1.67, Hb | |||||
| 13 | 27.4, CH2 | 1.99, Ha | 25.3, CH2 | 1.79, Ha | 35.2, CH2 | 2.54, ddd (15.3, 9.8, 6.9), Ha |
| 1.51, Hb | 1.55, Hb | 1.51, ddd (15.3, 8.1, 2.2), Hb | ||||
| 14 | 45.3, CH | 2.21 | 51.1, CH | 1.93, td (10.0, 4.8) | 47.1, CH | 2.16 |
| 15 | 142.7, C | 90.3, C | 143.3, C | |||
| 16 | 114.9, CH2 | 5.11, br s, Ha | 24.3,*2 CH3 | 1.51,*3 s | 113.0, CH2 | 4.75, br s, Ha |
| 4.91, br s, Hb | 4.59, br s, Hb | |||||
| 17 | 67.4, CH2 | 4.64, br s | 24.2,*2 CH3 | 1.50,*3 s | 18.5, CH3 | 1.60, br s |
| 1′ | 162.7, C | 164.2, C | 162.7, C | |||
| 2′ | 135.6, C | 137.3, C | 135.6, C | |||
| 3′ | 109.8, CH | 6.50, s | 110.2, CH | 6.52, s | 110.0, CH | 6.53, s |
| 4′ | 132.1, C | 133.7, C | 132.0, C | |||
| 5′/9′ | 129.9, CH | 7.67 | 130.9, CH | 7.70 | 129.8, CH | 7.65 |
| 6′/8′ | 128.8, CH | 7.41 | 129.9, CH | 7.41 | 128.9, CH | 7.40 |
| 7′ | 129.1, CH | 7.35 | 130.3, CH | 7.35 | 129.4, CH | 7.36 |
| 10′ | 165.0, C | 165.6, C | 164.2, C | |||
| 11′ | 108.4, C | 109.9, C | 108.3, C | |||
| 12′ | 32.9, CH | 2.67, sept (6.9) | 33.8, CH | 2.61, sept (6.9) | 32.5, CH | 2.71, sept (6.9) |
| 13′*1 | 15.2, CH3 | 1.07, d (6.9) | 15.6, CH3 | 1.06, d (6.9) | 15.2, CH3 | 1.11, d (6.9) |
| 14′*1 | 14.5, CH3 | 1.07, d (6.9) | 14.8, CH3 | 1.04, d (6.9) | 14.6, CH3 | 1.11, d (6.9) |
aThe data recorded in CDCl3 (600 MHz for 1H and 150 MHz for 13C).
bThe data recorded in CD3OD (600 MHz for 1H and 150 MHz for 13C).
cIndiscernible signals from overlap or complex multiplicity are reported without designating multiplicity.
*The assignment maybe exchanged in each group.
Figure 3The experimental ECD spectra of 1, 4, and 7 and the simulated ECD spectrum of 1 (the sum of 4 and 7).
Figure 4The experimental ECD spectra of 2, 4, and 8 and the simulated ECD spectrum of 2 (the sum of 4 and 8).
Figure 5Key NOESY correlations of 3.
Figure 6The experimental ECD spectra of 3, 4, and 9 and the simulated ECD spectrum of 3 (the sum of 4 and 9).
The antimicrobial activities of 1–9.
| Anti- | Anti- | ||
|---|---|---|---|
| Comp. | MIC (μg/mL) | Comp. | MIC (μg/mL) |
|
| 64 |
| 128 |
|
| 64 |
| 128 |
|
| 32 |
| 128 |
|
| 128 |
| 128 |
|
| 64 |
| 128 |
|
| 4 |
| 4 |
|
| 128 |
| 128 |
|
| 128 |
| 128 |
|
| 64 |
| 128 |
| *Tobramycin | 0.5 | *Itraconazole | 0.5 |
*Positive control.
Figure 7Plausible biosynthetic pathway of compounds 1−3.